RECRUITING

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Description

This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.

Conditions

Advanced Malignant Tumors
Talk to us

Related Conditions:

Advanced Malignant Tumors

Study Overview

On this page

Study Details

Study overview

This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.

A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Condition
Advanced Malignant Tumors
Intervention / Treatment

-

Contacts and Locations

Hackensack

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States, 07601

Allentown

Local Institution - 0020, Allentown, Pennsylvania, United States, 18103

Germantown

The West Clinic, PLLC dba West Cancer Center, Germantown, Tennessee, United States, 38138

Dallas

Local Institution - 0025, Dallas, Texas, United States, 75390

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participant must be ≥ 18 years of age.
  • * Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:.
  • * Part 1A: clear-cell renal cell carcinoma (ccRCC) or clear-cell ovarian cancer (ccOC).
  • * Parts 2A, 1D, 2D: ccRCC.
  • * Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1.
  • * Participants must have measurable disease per RECIST v1.1.
  • * Untreated central nervous system (CNS) metastases.
  • * Leptomeningeal metastasis (carcinomatous meningitis).
  • * Impaired cardiac function or clinically significant cardiac disease.
  • * For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bristol-Myers Squibb,

Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

2027-10-15